Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Landgren, Ola  [Clear All Filters]
2015
Landgren O, Owen RG. Better therapy requires better response evaluation: Paving the way for minimal residual disease testing for every myeloma patient. Cytometry B Clin Cytom. 2015.
Smith E, Devlin SM, Orlando E, Landau H, Lesokhin AM, Chung DJ, Hassoun H, Lendvai N, Landgren O, Giralt S, et al. CD34-selected allogeneic hematopoietic stem cell transplantation for patients with relapsed, high-risk multiple myeloma. Biol Blood Marrow Transplant. 2015.
2020
Alsina M, Landgren O, Raje N, Niesvizky R, Bensinger WI, Berdeja JG, Kovacsovics T, Vesole DH, Fang B, Kimball AS, et al. A phase 1b study of once-weekly carfilzomib combined with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma. Am J Hematol. 2020.
Bal S, Landau HJ, Shah GL, Scordo M, Dahi P, Lahoud OB, Hassoun H, Hultcrantz M, Korde N, Lendvai N, et al. Stem Cell Mobilization and Autograft Minimal Residual Disease Negativity 1 with Novel Induction Regimens in Multiple Myeloma. Biol Blood Marrow Transplant. 2020.
2022
Fatoki RAyoolu, Koehn K, Kelkar A, Hadidi SAl, Mehra N, Mian H, Landgren O, Kazandjian D, Hoffman J, Sborov DW, et al. Global Myeloma Trial Participation and Drug Access in the Era of Novel Therapies. JCO Glob Oncol. 2022;8:e2200119.
2023
Coffey DG, Maura F, Gonzalez-Kozlova E, J Diaz-Mejia J, Luo P, Zhang Y, Xu Y, Warren EH, Dawson T, Lee B, et al. Immunophenotypic correlates of sustained MRD negativity in patients with multiple myeloma. Nat Commun. 2023;14(1):5335.
Diamond BT, Ziccheddu B, Maclachlan KH, Taylor J, Boyle EMary, Ossa JEsteban Ar, Jahn TJacob, Affer M, Totiger TM, Coffey DG, et al. Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures. Blood. 2023.
2024
Maura F, Rajanna ARaj, Ziccheddu B, Poos AM, Derkach A, Maclachlan K, Durante M, Diamond B, Papadimitriou M, Davies F, et al. Genomic Classification and Individualized Prognosis in Multiple Myeloma. J Clin Oncol. 2024:JCO2301277.